Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes

2018267 citationsJournal Articlehybrid Open Access

Authors

W. Timothy Garvey · Birmingham VA Medical Center

Luc Van Gaal · Antwerp University Hospital

Lawrence A. Leiter · St. Michael's Hospital

Ujjwala Vijapurkar · Janssen (United States)

James F. List · Janssen (United States)

Robert Cuddihy · Janssen (United States)

Jimmy Ren ·

Abstract

These results indicate that canagliflozin may improve adipose tissue function and induce changes in serum leptin, adiponectin, and IL-6 that favorably impact insulin sensitivity and cardiovascular disease risk.

Topics & Keywords

Diabetes Treatment and Management Pancreatic function and diabetes Metabolism, Diabetes, and Cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Metabolism

Volume 85, pp. 32-37

DOI: 10.1016/j.metabol.2018.02.002

Field-Weighted Citation Impact: 19.84